Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Inclusion Criteria: * Histologically confirmed cutaneous T-cell lymphoma, including mycosis fungoides/Sézary syndrome * Stage IB-IV disease * Relapsed or refractory disease OR intolerant to ≥ 1 prior systemic therapy * Measurable disease by radiological imaging or clinical finding * Age Over 18 * Performance status Karnofsky 70-100% * Hematopoietic * WBC \> 2,000/mm\^3 * Absolute neutrophil count \> 1,500/mm\^3 * Platelet count \> 75,000/mm\^3 * Hemoglobin \> 8.0 g/dL * Hepatic * Bilirubin \< 2 times upper limit of normal (ULN) * AST and ALT \< 3 times ULN * Renal * Creatinine \< 1.5 times ULN * Creatinine clearance ≥ 30 mL/min * Negative pregnancy test * Fertile patients must use effective contraception * More than 3 months since prior high-dose chemotherapy * More than 30 days since prior and no other concurrent investigational drugs Exclusion Criteria: * history of myelodysplastic syndromes * evidence of CNS disease * pregnant or nursing * peripheral neuropathy ≥ grade 2 * hypersensitivity to bortezomib, boron, or mannitol * serious medical condition or psychiatric illness that would preclude study participation * concurrent immunotherapy * concurrent chemotherapy * concurrent steroid dose \> 10 mg/day of prednisone or its equivalent * concurrent radiotherapy * concurrent surgery for the malignancy